Business
AMN Healthcare provides healthcare staffing and workforce technology.
AMN Healthcare contracted revenue, reported a net loss, generated positive free cash flow at a -2.0% operating margin. The company reported a loss and negative margin while still generating positive free cash flow.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 8.5%Watch
- Profitability — The net loss narrowed from $146.979M to $95.702MOK
- Cash flow — Free cash flow declined 2.4% to $233.828M from $239.527MWatch
- Margins — Operating margin expanded 141 bps to -2.03%OK
- Accounting — The company reported a loss and negative margin while still generating positive free cash flowNote
- Insiders — 0 purchases and 1 salesNote
Where the revenue comes from
Fiscal 2025, as AMN HEALTHCARE SERVICES INC reports it. History and quarterly detail are in the app.
- Nurse and Allied Solutions$1.6B
- Physician and Leadership Solutions$696.4M
- Technology and Workforce Solutions$386.7M
Leadership changes
From AMN HEALTHCARE SERVICES INC's own filings, the day they're filed.
- Douglas D. Wheat · Chairman · departureeff. 2025-02-04
- Mark G. Foletta · Chairman · appointmenteff. 2024-11-11
- Douglas D. Wheat · Chairman · departureeff. 2024-11-09
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-06
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-05-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AMN HEALTHCARE SERVICES INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.